Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab growth study in children with severe atopic dermatitis
NCT07187089Phase 4Withdrawn
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
01
Overview
Phase 4, open-label, single-arm trial of dupilumab in atopic dermatitis (AD), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Improvement of ≥5 percentile in height-for-age percentile on the Centers for Disease Control and Prevention (CDC) growth chart at Week 52. Planned start Nov 2025; status: withdrawn.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07187089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07187089.